ALR Technologies: Penny Stock, Recent FDA Clearance, Enormous Potential

ALR Technologies (ALRT)

ALR Technologies Inc. (OTCBB: ALRT), an innovative medical device company, offers a unique software solution aimed at improving patient adherence to care plans  in the diabetes industry working alongside companies like Abbott Laboratories (NYSE: ABT) and Bayer AG (PINK: BAYRY) that develop diabetes testing supplies.

Meanwhile, diabetes is becoming a growing problem around the world. By some estimates, 500 million people, or 1 in 10 adults, will have diabetes by 2030. For more information on these trends and statistics, investors can see the following article:

Undervalued Stock in an Enormous Industry

ALR Technologies has a market capitalization of just $18 million, despite having a late-stage medical device within a multi-billion dollar industry. According to the American Diabetes Association, approximately 25.8 million adults and children have the disease in the U.S., which represents some 8.3% of the population as of 2011 and cost some $174 billion in 2007.

Despite its growing prevalence, many forms of diabetes are preventable. According to the National Institutes of Health, studies have shown that people at high risk for diabetes can prevent or delay onset of the disease by losing 5-7% of their weight. And even if they have diabetes, many of its complications can be avoided by adhering to a diabetes management plan.

The problem is that many people don’t follow their diabetes management plan. Diabetes patients are responsible for more than 95% of their own care and many healthcare professionals express frustration that patients don’t follow diet or exercise plans, check blood sugars or even take their medications as prescribed.

HeC System Makes a World of Difference

ALR Technologies’ Health-e-Connect (HeC) System is an internet-based platform for diabetes patients and their healthcare providers to improve communication and monitoring of a patient’s health management program.  For instance, the software will upload data from a patient’s glucose meter into a database that allows healthcare providers to quickly assess user compliance and test results compared to targets.

In August 2010, Diabetes Care published the results of a trial conducted by Dr. Hugh Tildesley, et al, comparing insulin dependent diabetes patients receiving conventional care with patients that had additional follow-up via an internet based blood glucose monitoring system (IBGMS). The HeC System was the IBGMS deployed in the trial. The study showed A1c dropping from 8.8% to 7.6% over 6 months in the diabetes patients who had the additional IBGMS follow-up. The A1c test is important in diabetes treatment management as a long-term measure of control over blood glucose. In general, every 1% drop in A1c may reduce the risk of microvascular complications by 40%.

In July of 2010, the company submitted a 510(k) application to the FDA for its proprietary HeC System to enable it to market the technology in the U.S. On October 17, 2011, ALR Technologies announced the 510(k) clearance of its HeC system for remote monitoring of patients in support of diabetes management.

A Solid Investment Opportunity

ALR Technologies represents an early stage investment opportunity. With a 510(k) cleared medical device available for the market, the company’s $18 million market capitalization may be significantly undervalued.  Given the efficacy of IBGMS as reported by Dr. Hugh Tildesley, et al, the sales potential of the HeC system could be very large.

For more information on ALR Technologies, please see the following resources:

Company Website

Latest SEC Filings

ALR Technologies (ALRT) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated twenty thousand dollars per month for three months of consultation and journalism services and to manage a comprehensive investor relations/awareness program by ALR Technologies. Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Stocks Mixed on Monday

Stocks Mixed on Monday(0)

The Dow Jones industrial average topped 16,000 for the first time ever Monday, while the S&P 500 briefly surpassed 1,800. The Dow retreated from the 16,000 level, but still gained 14.32 points from Friday”s all-time high close, to 15,976. The S&P 500 index dipped 6.65 points to 1,791.53. The NASDAQ fell 36.90 points to 3,949.07

Cellceutix Targeting Gram-Negative and Candida Fungal Infections

Cellceutix Targeting Gram-Negative and Candida Fungal Infections(0)

Monday morning, Cellceutix Corp. (OTCQB: CTIX) provided shareholders with an update on its progress with filing an Investigational New Drug application with the FDA for its anti-psoriasis drug. Additionally - and taking the headline - the company delivered to shareholders news that it has made additional promising advancements with its pipeline to potentially address diseases

Catalyst Pharmaceutical Partners Stock Chart Analysis Video

Catalyst Pharmaceutical Partners Stock Chart Analysis Video(0)

The Catalyst Pharmaceutical Partners (NASDAQ: CPRX) stock chart formed a piercing line reversal pattern on Wednesday and Thursday that was confirmed with a sharp move upwards on Friday. Technical traders will be watching support around the 200 day moving average at $1.25 on any pullback, but for the time being, the chart looks to be

EnteroMedics Stock Chart Analysis Video

EnteroMedics Stock Chart Analysis Video(0)

The EnteroMedics (NASDAQ:ETRM) chart has been making higher highs and higher lows since forming a double bottom early in the year. The chart is holding over the 50-day moving average and inching higher each day as it tries to gain momentum to make the next leg up in the channel. EnteroMedics is a medical device

NXT-ID Authentication Using Face and Voice Recognition

NXT-ID Authentication Using Face and Voice Recognition(0)

There’s a Wocket in My Pocket! may soon not just be a sentence from the mouths of children after reading the rhyming book by Dr. Seuss. There was plenty of made-up ridiculousness in the iconic book, such as a bofa on the sofa, but there is nothing fictitious about the Wocket, a next-generation payment and

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.